Stockreport

Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138

Supernus Pharmaceuticals, Inc.  (SUPN) 
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.supernus.com
PDF Companies to Collaborate on Phase II Development for NV-5138 in DepressionNV-5138 is a Novel First-in-Class Activator of mTORC1Supernus Receives Exclusive Option to Lice [Read more]